- Home
- DHI vs TAK Comparison
DHI vs TAK Comparison
Compare DHI & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHI
- TAK
- Stock Information
- Founded
- DHI 1978
- TAK 1781
- Country
- DHI United States
- TAK Japan
- Employees
- DHI N/A
- TAK N/A
- Industry
- DHI Homebuilding
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- DHI Consumer Discretionary
- TAK Health Care
- Exchange
- DHI Nasdaq
- TAK Nasdaq
- Market Cap
- DHI 44.0B
- TAK 42.2B
- IPO Year
- DHI 1992
- TAK N/A
- Fundamental
- Price
- DHI $121.25
- TAK $14.71
- Analyst Decision
- DHI Buy
- TAK
- Analyst Count
- DHI 16
- TAK 0
- Target Price
- DHI $170.47
- TAK N/A
- AVG Volume (30 Days)
- DHI 4.2M
- TAK 2.5M
- Earning Date
- DHI 04-17-2025
- TAK 05-08-2025
- Dividend Yield
- DHI 1.32%
- TAK 4.01%
- EPS Growth
- DHI N/A
- TAK 15.39
- EPS
- DHI 13.25
- TAK 0.83
- Revenue
- DHI $35,315,300,000.00
- TAK $29,124,927,177.00
- Revenue This Year
- DHI $0.03
- TAK $8.53
- Revenue Next Year
- DHI $5.41
- TAK N/A
- P/E Ratio
- DHI $9.15
- TAK $34.69
- Revenue Growth
- DHI N/A
- TAK 9.83
- 52 Week Low
- DHI $110.44
- TAK $12.58
- 52 Week High
- DHI $199.85
- TAK $15.37
- Technical
- Relative Strength Index (RSI)
- DHI 45.63
- TAK 52.69
- Support Level
- DHI $116.66
- TAK $13.60
- Resistance Level
- DHI $122.96
- TAK $15.37
- Average True Range (ATR)
- DHI 6.26
- TAK 0.33
- MACD
- DHI -0.20
- TAK -0.03
- Stochastic Oscillator
- DHI 50.35
- TAK 62.71
About DHI D.R. Horton Inc.
D.R. Horton is a leading homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.